Quote this publication Share Print

REMODULIN

-
Opinions on drugs - Posted on Jul 08 2014

Reason for request

Inclusion

-  


Clinical Benefit

Insufficient

Insufficient to justify reimbursement by National Health Insurance in the treatment of idiopathic or hereditary PAH in functional class III patients


Clinical Added Value

Not applicable to the file

Not applicable